WILMINGTON, MASSACHUSETTS -- (MARKET WIRE) -- 03/13/07 -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its corporate highlights and year end financial results press release will be issued on Friday, March 16th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

                Friday, March 16th - 8:30 a.m. Eastern
  If calling from the US or Canada use the following toll-free number:
                               800.647.4314
                              Password - DUSA

                      For International callers use
                              641.297.7663

              A recorded replay of the call will be available
                    North American callers 877.863.0350
                    International callers 858.244.1268

The call will be accessible on our web site approximately 1 hour following the call at www.dusapharma.com.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne. DUSA's other dermatology products include Nicomide®, and the AVAR® line. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA.

Contacts:
DUSA Pharmaceuticals, Inc.
Shari Lovell
Director, Shareholder Services
(416) 363-5059
Website: www.dusapharma.com